机器人保留乳头乳房切除术与直接植入物重建的安全性和可行性——来自亚洲最大中心之一的见解。

IF 2.9 3区医学 Q2 ONCOLOGY

Clinical breast cancer Pub Date : 2024-12-25 DOI:10.1016/j.clbc.2024.12.013

Yu-Meng Claire Lin , Su Ann Lui , Mei-Yen Chen , Yu-Yu Chou , Fiona Tsui-Fen Cheng

{"title":"机器人保留乳头乳房切除术与直接植入物重建的安全性和可行性——来自亚洲最大中心之一的见解。","authors":"Yu-Meng Claire Lin , Su Ann Lui , Mei-Yen Chen , Yu-Yu Chou , Fiona Tsui-Fen Cheng","doi":"10.1016/j.clbc.2024.12.013","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The use of robotic-assisted nipple-sparing mastectomy (R-NSM) with immediate direct-to-implant (DTI) reconstruction in treatment of breast cancer has been a controversial topic. The adoption of robotic surgery in breast cancer treatment has gained traction globally due to its minimally invasive nature, potential for improved cosmetic outcomes and better intraoperative visualization. This study provides insights on safety and feasibility robotic mastectomy at one of the largest centers in Asia.</div></div><div><h3>Methods</h3><div>This retrospective study included patients who underwent robotic nipple-sparing mastectomy (R-NSM) with immediate direct-to-implant (DTI) reconstruction from April 2018 to September 2024. Our endpoints were mainly focused on perioperative outcomes, patient satisfaction, and oncologic outcomes.</div></div><div><h3>Results</h3><div>A total of 266 procedures were included in our series, with 233 patients undergoing unilateral R-NSM with either DTI reconstruction or a tissue expander, and 33 patients underwent surgery on both breasts. Postoperative complications were recorded in 11 patients (4.14 %). The median follow-up of this study is 37.2 ± 23.3 months. Locoregional recurrence (LRR) was observed in 6 patients (2.5 %), with isolated skin recurrence being the most common. Distant metastasis was observed in 9 patients (3.86 %). The 3-year overall survival rate was 98.3 %.</div></div><div><h3>Conclusion</h3><div>Robotic NSM is a safe and feasible novel minimal invasive surgical approach for breast cancer surgery, providing both excellent cosmetic results and oncological outcomes that are noninferior to conventional or endoscopic approaches.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 3","pages":"Pages 277-282"},"PeriodicalIF":2.9000,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Safety and Feasibility of Robotic Nipple-Sparing Mastectomy With Immediate Direct-to-Implant Reconstruction – Insights From the One of the Largest Centers in Asia\",\"authors\":\"Yu-Meng Claire Lin , Su Ann Lui , Mei-Yen Chen , Yu-Yu Chou , Fiona Tsui-Fen Cheng\",\"doi\":\"10.1016/j.clbc.2024.12.013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>The use of robotic-assisted nipple-sparing mastectomy (R-NSM) with immediate direct-to-implant (DTI) reconstruction in treatment of breast cancer has been a controversial topic. The adoption of robotic surgery in breast cancer treatment has gained traction globally due to its minimally invasive nature, potential for improved cosmetic outcomes and better intraoperative visualization. This study provides insights on safety and feasibility robotic mastectomy at one of the largest centers in Asia.</div></div><div><h3>Methods</h3><div>This retrospective study included patients who underwent robotic nipple-sparing mastectomy (R-NSM) with immediate direct-to-implant (DTI) reconstruction from April 2018 to September 2024. Our endpoints were mainly focused on perioperative outcomes, patient satisfaction, and oncologic outcomes.</div></div><div><h3>Results</h3><div>A total of 266 procedures were included in our series, with 233 patients undergoing unilateral R-NSM with either DTI reconstruction or a tissue expander, and 33 patients underwent surgery on both breasts. Postoperative complications were recorded in 11 patients (4.14 %). The median follow-up of this study is 37.2 ± 23.3 months. Locoregional recurrence (LRR) was observed in 6 patients (2.5 %), with isolated skin recurrence being the most common. Distant metastasis was observed in 9 patients (3.86 %). The 3-year overall survival rate was 98.3 %.</div></div><div><h3>Conclusion</h3><div>Robotic NSM is a safe and feasible novel minimal invasive surgical approach for breast cancer surgery, providing both excellent cosmetic results and oncological outcomes that are noninferior to conventional or endoscopic approaches.</div></div>\",\"PeriodicalId\":10197,\"journal\":{\"name\":\"Clinical breast cancer\",\"volume\":\"25 3\",\"pages\":\"Pages 277-282\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-12-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical breast cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1526820924003641\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical breast cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1526820924003641","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：机器人辅助保留乳头乳房切除术（R-NSM）与直接植入（DTI）重建在乳腺癌治疗中的应用一直是一个有争议的话题。机器人手术由于其微创性、改善美容效果的潜力和更好的术中可视化，在乳腺癌治疗中获得了全球的关注。这项研究提供了安全性和可行性的见解，机器人乳房切除术在亚洲最大的中心之一。方法：本回顾性研究包括2018年4月至2024年9月期间接受机器人保留乳头乳房切除术（R-NSM）并立即直接植入（DTI）重建的患者。我们的终点主要集中在围手术期结果、患者满意度和肿瘤预后。结果：我们的研究共纳入266例手术，其中233例患者接受单侧R-NSM，同时接受DTI重建或组织扩张术，33例患者接受双侧乳房手术。术后并发症11例（4.14%）。中位随访时间为37.2±23.3个月。局部复发（LRR） 6例（2.5%），以孤立性皮肤复发最为常见。远处转移9例（3.86%）。3年总生存率为98.3%。结论：机器人NSM是一种安全可行的新型微创乳腺癌手术入路，具有良好的美容效果和肿瘤预后，不逊色于传统或内镜入路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Safety and Feasibility of Robotic Nipple-Sparing Mastectomy With Immediate Direct-to-Implant Reconstruction – Insights From the One of the Largest Centers in Asia

Background

The use of robotic-assisted nipple-sparing mastectomy (R-NSM) with immediate direct-to-implant (DTI) reconstruction in treatment of breast cancer has been a controversial topic. The adoption of robotic surgery in breast cancer treatment has gained traction globally due to its minimally invasive nature, potential for improved cosmetic outcomes and better intraoperative visualization. This study provides insights on safety and feasibility robotic mastectomy at one of the largest centers in Asia.

Methods

This retrospective study included patients who underwent robotic nipple-sparing mastectomy (R-NSM) with immediate direct-to-implant (DTI) reconstruction from April 2018 to September 2024. Our endpoints were mainly focused on perioperative outcomes, patient satisfaction, and oncologic outcomes.

Results

A total of 266 procedures were included in our series, with 233 patients undergoing unilateral R-NSM with either DTI reconstruction or a tissue expander, and 33 patients underwent surgery on both breasts. Postoperative complications were recorded in 11 patients (4.14 %). The median follow-up of this study is 37.2 ± 23.3 months. Locoregional recurrence (LRR) was observed in 6 patients (2.5 %), with isolated skin recurrence being the most common. Distant metastasis was observed in 9 patients (3.86 %). The 3-year overall survival rate was 98.3 %.

Conclusion

Robotic NSM is a safe and feasible novel minimal invasive surgical approach for breast cancer surgery, providing both excellent cosmetic results and oncological outcomes that are noninferior to conventional or endoscopic approaches.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical breast cancer 医学-肿瘤学

CiteScore

5.40

自引率

3.20%

发文量

174

审稿时长

48 days

期刊介绍： Clinical Breast Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of breast cancer. Clinical Breast Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of breast cancer. The main emphasis is on recent scientific developments in all areas related to breast cancer. Specific areas of interest include clinical research reports from various therapeutic modalities, cancer genetics, drug sensitivity and resistance, novel imaging, tumor genomics, biomarkers, and chemoprevention strategies.